MICHAEL A DAVIES to Antineoplastic Agents
This is a "connection" page, showing publications MICHAEL A DAVIES has written about Antineoplastic Agents.
Connection Strength
0.896
-
Finding the right balance of BRAF inhibition in melanoma. Cancer Discov. 2014 May; 4(5):510-2.
Score: 0.095
-
Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol. 2014 Feb 01; 87(3):381-9.
Score: 0.093
-
Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin Cancer Res. 2013 Oct 01; 19(19):5310-9.
Score: 0.092
-
Overcoming resistance to MAPK pathway inhibitors. J Natl Cancer Inst. 2013 Jan 02; 105(1):9-10.
Score: 0.087
-
Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol. 2010 Sep 01; 80(5):568-74.
Score: 0.072
-
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther. 2010 Feb; 9(2):257-67.
Score: 0.071
-
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther. 2009 Aug; 8(8):2079-85.
Score: 0.069
-
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell. 2020 12 14; 38(6):829-843.e4.
Score: 0.037
-
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
Score: 0.028
-
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
Score: 0.028
-
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res. 2015 Nov 01; 21(21):4801-10.
Score: 0.026
-
A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).
Score: 0.025
-
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest. 2014 Mar; 124(3):1406-17.
Score: 0.024
-
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer. 2013 Sep 03; 109(5):1085-92.
Score: 0.023
-
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013 Feb 01; 19(3):657-67.
Score: 0.022
-
Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2. J Immunother. 2012 Nov-Dec; 35(9):711-5.
Score: 0.021
-
The role of the PI3K-AKT pathway in melanoma. Cancer J. 2012 Mar-Apr; 18(2):142-7.
Score: 0.020
-
Targeted therapy for brain metastases. Adv Pharmacol. 2012; 65:109-42.
Score: 0.020
-
Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol Cancer. 2010 Jun 09; 9:140.
Score: 0.018
-
Point mutations of protein kinases and individualised cancer therapy. Expert Opin Pharmacother. 2006 Nov; 7(16):2243-61.
Score: 0.014
-
Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients. J Cutan Pathol. 2017 Dec; 44(12):1080-1086.
Score: 0.008
-
Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res. 2010 Mar 15; 16(6):1834-44.
Score: 0.004